|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
Synthesis and characterization of novel oxazines and demonstration that they specifically target cyclooxygenase 2статья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 19 сентября 2017 г.
- Авторы: Srinivas V., Chakrabhavi Dhananjaya Mohan, Baburajeev CP, Shobith Rangappa, Swamy Jagadish, Fuchs Julian E., Sukhorukov Alexey Yu, Mason Daniel J., Sharath Kumar Kothanahally Shivaramu, Mahendra Madegowda, Andreas Bender, Kanchugarakoppal Subbegowda Rangappa
- Журнал: Bioorganic and Medicinal Chemistry Letters
- Том: 25
- Номер: 15
- Год издания: 2015
- Издательство: Pergamon Press Ltd.
- Местоположение издательства: United Kingdom
- Первая страница: 2931
- Последняя страница: 2936
- DOI: 10.1016/j.bmcl.2015.05.047
- Аннотация: In the present study, we used solution combustion synthesis-bismuth oxide (Bi2O3) as catalyst for the simple and efficient synthesis of 1,2-oxazine based derivatives of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazoles, 1-arylpiperazine and carbazoles. (4aR,8aR)-4-(4-Methoxyphenyl)-3-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-4a,5,6,7,8,8a-hexahydro-4H-benzo[e][1,2]oxazine was found to be the most potent compound with a high degree of selectivity in inhibition towards COX2 (1.7 μM) over COX1 (40.4 μM) demonstrating the significance of 1,2-oxazine derivatives in developing COX2 specific inhibitors. Molecular docking analyses demonstrated that an isoleucine residue in the active site of COX1 is responsible for lower affinity to COX1 and increased potency towards COX2. Overall, our study reveals that the new 1,2-oxazine-based small molecules qualify as lead structures in developing COX2-specific inhibitors for anti-inflammatory therapy.
- Добавил в систему: Сухоруков Алексей Юрьевич